FDA clears Accuray Dose Control System
The FDA has granted 510(k) clearance for Accuray, a Sunnyvale, Calif.-based radiation oncology company, to market the Dose Control System (DCS), a feature for Accuray’s TomoTherapy System.
With DCS, the TomoTherapy radiation therapy system becomes the first dose servo-controlled helical delivery system and provides dose stability throughout complex rotational treatments, according to Accuray. Static delivery should also see more consistent dose rates at every gantry angle, the company stated.
DCS automatically adjusts controls that were previously manual processes, meaning small variations in dose rate are corrected by the system with fewer interruptions. The application also stabilizes output over longer duration treatments, such as total marrow and total body irradiation.
With DCS, the TomoTherapy radiation therapy system becomes the first dose servo-controlled helical delivery system and provides dose stability throughout complex rotational treatments, according to Accuray. Static delivery should also see more consistent dose rates at every gantry angle, the company stated.
DCS automatically adjusts controls that were previously manual processes, meaning small variations in dose rate are corrected by the system with fewer interruptions. The application also stabilizes output over longer duration treatments, such as total marrow and total body irradiation.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.